A cytomegalovirus-based vaccine expressing a single tumor-specific CD8 + T-cell epitope delays tumor growth in a murine model of prostate cancer

Elena N. Klyushnenkova, Diana V. Kouiavskaia, Christopher J. Parkins, Patrizia Caposio, Sara Botto, Richard B. Alexander, Michael A. Jarvis

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Cytomegalovirus (CMV) is a highly immunogenic virus that results in a persistent, life-long infection in the host typically with no ill effects. Certain unique features of CMV, including its capacity to actively replicate in the presence of strong host CMV-specific immunity, may give CMV an advantage compared with other virus-based vaccine delivery platforms. In the present study, we tested the utility of mouse CMV (mCMV)-based vaccines expressing human prostate-specific antigen (PSA) for prostate cancer immunotherapy in double-transgenic mice expressing PSA and HLA-DRB1*1501 (DR2bxPSA F1 mice). We assessed the capacity of 2 mCMV-based vectors to induce PSA-specific CD8 T-cell responses and affect the growth of PSA-expressing Transgenic Adenocarcinoma of the Mouse Prostate tumors (TRAMP-PSA). In the absence of tumor challenge, immunization with mCMV vectors expressing either a H2-D b-restricted epitope PSA65-73 (mCMV/PSA65-73) or the full-length gene for PSA (mCMV/PSAFL) induced comparable levels of CD8 T-cell responses that increased (inflated) with time. Upon challenge with TRAMP-PSA tumor cells, animals immunized with mCMV/PSA 65-73 had delay of tumor growth and increased PSA-specific CD8 T-cell responses, whereas animals immunized with mCMV/PSAFL showed progressive tumor growth and no increase in number of splenic PSA 65-73-specific T cells. The data show that a prototype CMV-based prostate cancer vaccine can induce an effective antitumor immune response in a "humanized" double-transgenic mouse model. The observation that mCMV/PSAFL is not effective against TRAMP-PSA is consistent with our previous findings that HLA-DRB1*1501-restricted immune responses to PSA are associated with suppression of effective CD8 T-cell responses to TRAMP-PSA tumors.

Original languageEnglish (US)
Pages (from-to)390-399
Number of pages10
JournalJournal of Immunotherapy
Volume35
Issue number5
DOIs
StatePublished - Jun 2012

Fingerprint

Cytomegalovirus Vaccines
T-Lymphocyte Epitopes
Prostate-Specific Antigen
Prostatic Neoplasms
Growth
Neoplasms
Cytomegalovirus
T-Lymphocytes
Transgenic Mice
HLA-DRB1 Chains
Muromegalovirus
Viruses
Cancer Vaccines

Keywords

  • Cancer vaccine
  • Cytomegalovirus
  • HLA-DR2 transgenic mice
  • Prostate cancer
  • Prostate-specific antigen

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Cancer Research
  • Pharmacology

Cite this

A cytomegalovirus-based vaccine expressing a single tumor-specific CD8 + T-cell epitope delays tumor growth in a murine model of prostate cancer. / Klyushnenkova, Elena N.; Kouiavskaia, Diana V.; Parkins, Christopher J.; Caposio, Patrizia; Botto, Sara; Alexander, Richard B.; Jarvis, Michael A.

In: Journal of Immunotherapy, Vol. 35, No. 5, 06.2012, p. 390-399.

Research output: Contribution to journalArticle

Klyushnenkova, Elena N. ; Kouiavskaia, Diana V. ; Parkins, Christopher J. ; Caposio, Patrizia ; Botto, Sara ; Alexander, Richard B. ; Jarvis, Michael A. / A cytomegalovirus-based vaccine expressing a single tumor-specific CD8 + T-cell epitope delays tumor growth in a murine model of prostate cancer. In: Journal of Immunotherapy. 2012 ; Vol. 35, No. 5. pp. 390-399.
@article{4e2c51091666476da91ca5e8fd8392ea,
title = "A cytomegalovirus-based vaccine expressing a single tumor-specific CD8 + T-cell epitope delays tumor growth in a murine model of prostate cancer",
abstract = "Cytomegalovirus (CMV) is a highly immunogenic virus that results in a persistent, life-long infection in the host typically with no ill effects. Certain unique features of CMV, including its capacity to actively replicate in the presence of strong host CMV-specific immunity, may give CMV an advantage compared with other virus-based vaccine delivery platforms. In the present study, we tested the utility of mouse CMV (mCMV)-based vaccines expressing human prostate-specific antigen (PSA) for prostate cancer immunotherapy in double-transgenic mice expressing PSA and HLA-DRB1*1501 (DR2bxPSA F1 mice). We assessed the capacity of 2 mCMV-based vectors to induce PSA-specific CD8 T-cell responses and affect the growth of PSA-expressing Transgenic Adenocarcinoma of the Mouse Prostate tumors (TRAMP-PSA). In the absence of tumor challenge, immunization with mCMV vectors expressing either a H2-D b-restricted epitope PSA65-73 (mCMV/PSA65-73) or the full-length gene for PSA (mCMV/PSAFL) induced comparable levels of CD8 T-cell responses that increased (inflated) with time. Upon challenge with TRAMP-PSA tumor cells, animals immunized with mCMV/PSA 65-73 had delay of tumor growth and increased PSA-specific CD8 T-cell responses, whereas animals immunized with mCMV/PSAFL showed progressive tumor growth and no increase in number of splenic PSA 65-73-specific T cells. The data show that a prototype CMV-based prostate cancer vaccine can induce an effective antitumor immune response in a {"}humanized{"} double-transgenic mouse model. The observation that mCMV/PSAFL is not effective against TRAMP-PSA is consistent with our previous findings that HLA-DRB1*1501-restricted immune responses to PSA are associated with suppression of effective CD8 T-cell responses to TRAMP-PSA tumors.",
keywords = "Cancer vaccine, Cytomegalovirus, HLA-DR2 transgenic mice, Prostate cancer, Prostate-specific antigen",
author = "Klyushnenkova, {Elena N.} and Kouiavskaia, {Diana V.} and Parkins, {Christopher J.} and Patrizia Caposio and Sara Botto and Alexander, {Richard B.} and Jarvis, {Michael A.}",
year = "2012",
month = "6",
doi = "10.1097/CJI.0b013e3182585d50",
language = "English (US)",
volume = "35",
pages = "390--399",
journal = "Journal of Immunotherapy",
issn = "1524-9557",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - A cytomegalovirus-based vaccine expressing a single tumor-specific CD8 + T-cell epitope delays tumor growth in a murine model of prostate cancer

AU - Klyushnenkova, Elena N.

AU - Kouiavskaia, Diana V.

AU - Parkins, Christopher J.

AU - Caposio, Patrizia

AU - Botto, Sara

AU - Alexander, Richard B.

AU - Jarvis, Michael A.

PY - 2012/6

Y1 - 2012/6

N2 - Cytomegalovirus (CMV) is a highly immunogenic virus that results in a persistent, life-long infection in the host typically with no ill effects. Certain unique features of CMV, including its capacity to actively replicate in the presence of strong host CMV-specific immunity, may give CMV an advantage compared with other virus-based vaccine delivery platforms. In the present study, we tested the utility of mouse CMV (mCMV)-based vaccines expressing human prostate-specific antigen (PSA) for prostate cancer immunotherapy in double-transgenic mice expressing PSA and HLA-DRB1*1501 (DR2bxPSA F1 mice). We assessed the capacity of 2 mCMV-based vectors to induce PSA-specific CD8 T-cell responses and affect the growth of PSA-expressing Transgenic Adenocarcinoma of the Mouse Prostate tumors (TRAMP-PSA). In the absence of tumor challenge, immunization with mCMV vectors expressing either a H2-D b-restricted epitope PSA65-73 (mCMV/PSA65-73) or the full-length gene for PSA (mCMV/PSAFL) induced comparable levels of CD8 T-cell responses that increased (inflated) with time. Upon challenge with TRAMP-PSA tumor cells, animals immunized with mCMV/PSA 65-73 had delay of tumor growth and increased PSA-specific CD8 T-cell responses, whereas animals immunized with mCMV/PSAFL showed progressive tumor growth and no increase in number of splenic PSA 65-73-specific T cells. The data show that a prototype CMV-based prostate cancer vaccine can induce an effective antitumor immune response in a "humanized" double-transgenic mouse model. The observation that mCMV/PSAFL is not effective against TRAMP-PSA is consistent with our previous findings that HLA-DRB1*1501-restricted immune responses to PSA are associated with suppression of effective CD8 T-cell responses to TRAMP-PSA tumors.

AB - Cytomegalovirus (CMV) is a highly immunogenic virus that results in a persistent, life-long infection in the host typically with no ill effects. Certain unique features of CMV, including its capacity to actively replicate in the presence of strong host CMV-specific immunity, may give CMV an advantage compared with other virus-based vaccine delivery platforms. In the present study, we tested the utility of mouse CMV (mCMV)-based vaccines expressing human prostate-specific antigen (PSA) for prostate cancer immunotherapy in double-transgenic mice expressing PSA and HLA-DRB1*1501 (DR2bxPSA F1 mice). We assessed the capacity of 2 mCMV-based vectors to induce PSA-specific CD8 T-cell responses and affect the growth of PSA-expressing Transgenic Adenocarcinoma of the Mouse Prostate tumors (TRAMP-PSA). In the absence of tumor challenge, immunization with mCMV vectors expressing either a H2-D b-restricted epitope PSA65-73 (mCMV/PSA65-73) or the full-length gene for PSA (mCMV/PSAFL) induced comparable levels of CD8 T-cell responses that increased (inflated) with time. Upon challenge with TRAMP-PSA tumor cells, animals immunized with mCMV/PSA 65-73 had delay of tumor growth and increased PSA-specific CD8 T-cell responses, whereas animals immunized with mCMV/PSAFL showed progressive tumor growth and no increase in number of splenic PSA 65-73-specific T cells. The data show that a prototype CMV-based prostate cancer vaccine can induce an effective antitumor immune response in a "humanized" double-transgenic mouse model. The observation that mCMV/PSAFL is not effective against TRAMP-PSA is consistent with our previous findings that HLA-DRB1*1501-restricted immune responses to PSA are associated with suppression of effective CD8 T-cell responses to TRAMP-PSA tumors.

KW - Cancer vaccine

KW - Cytomegalovirus

KW - HLA-DR2 transgenic mice

KW - Prostate cancer

KW - Prostate-specific antigen

UR - http://www.scopus.com/inward/record.url?scp=84861233625&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861233625&partnerID=8YFLogxK

U2 - 10.1097/CJI.0b013e3182585d50

DO - 10.1097/CJI.0b013e3182585d50

M3 - Article

VL - 35

SP - 390

EP - 399

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1524-9557

IS - 5

ER -